PRIMARY STUDY
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Key Findings: Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV was able to delay the occurrence and to attenuate the magnitude of dyskinesia in an animal model of PD.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Spain
Year of Pub: 2020
Cannabinoids Studied: Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Injection
Cannabinoid Ratio: (THCV) 0 
Dosing Regimen: THCV was administered i.p. at 2 mg/kg
Treatment Duration: 2 weeks
Clinical Relevance: Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV delayed the occurrence and attenuated the magnitude of dyskinesia in an animal model of PD.
Citation: Espadas I, et al. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease. Neurobiol Dis. 2020; 141:104892. doi: 10.1016/j.nbd.2020.104892
Authors: Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, Fernández-Ruiz J, Moratalla R
